AKT1 and B-cell chronic lymphocytic leukemia: In primary CLL cells and in the stable CLL cell line MO1043, CX-4945 treatment led to decreased phosphorylation of Akt and PKC, which are downstream targets of PTEN and PI3K (Martins et al., 2014).